Trials / Completed
CompletedNCT02491905
Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients
Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Huons Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of HL tablet on reducing hepatic fat in non-alcoholic fatty liver disease patients. The patients are allocated to three groups; low dose, high dose, and placebo control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL tablet | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2015-07-08
- Last updated
- 2015-07-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02491905. Inclusion in this directory is not an endorsement.